A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously
every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines
of prior therapy.